Bevacizumab 7.5 mg/kg

DRUG2 trials

Sponsors

Hoffmann-La Roche, University of Chicago

Conditions

Advanced Non-squamous Non-Small Cell Lung CancerColorectal Cancer

Phase 3

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

CompletedNCT00069095

Hoffmann-La RocheColorectal Cancer

Start: 2003-07-31End: 2009-04-30Updated: 2016-10-06

Unknown Phase

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

CompletedNCT01063283

University of ChicagoAdvanced Non-squamous Non-Small Cell Lung Cancer

Start: 2010-03-31End: 2016-06-30Updated: 2019-11-18

Related Papers

Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2018-02-015 citations